Pfizer Installs Second 'Self-Driving' Lab
Pfizer has installed a second self-driving laboratory platform from Telescope Innovations. These labs use robotics and AI-driven experiment design to autonomously conduct, monitor, and optimize bioprocesses. The adoption signals a strategic move towards using 'Physical AI' to accelerate drug development and manufacturing in GMP-regulated settings.
- The collaboration is part of a multi-year master collaborative research agreement signed by Pfizer and Telescope in July 2024, which established a joint steering committee to guide technology development for accelerating pharmaceutical R&D. - Telescope's core technology often includes its flagship DirectInject-LC™ platform, which provides a critical link between physical chemistry and digital intelligence by connecting chemical reactors directly to liquid chromatography instruments for real-time online data analysis. - The "self-driving" aspect of these labs stems from a closed-loop integration of robotics for executing experiments, Process Analytical Technology (PAT) for real-time monitoring, and machine learning algorithms that design the next optimal experiment without human intervention, enabling 24/7 operation. - This move towards "Physical AI" aligns with the broader industry trend of adopting digital twins—virtual models of an entire bioprocess chain that use real-time data to predict critical quality attributes (CQAs) and reduce out-of-spec events in GMP manufacturing. - Regulatory bodies are adapting to these advancements; the European Medicines Agency (EMA), for example, is updating its GMP framework (Annex 11) and has introduced a new draft (Annex 22) specifically to provide guidance on the compliant use of AI in regulated environments. - Widespread adoption of such advanced AI systems in biopharma faces significant hurdles, including the high initial implementation costs, a shortage of professionals skilled in both data science and life sciences, and the challenge of integrating AI with legacy data infrastructure. - In the cell and gene therapy space, automation platforms from companies like Thermo Fisher Scientific and Pharmabotix are being developed to be modular and GMP-compliant, addressing complex workflows like inoculum preparation and cryovial filling to reduce manual touchpoints and increase reproducibility. - The installation of this second lab, completed in January 2026, represents a key milestone for the partnership, signaling a shift from collaborative R&D towards potential full-scale deployment of the technology.
